A pair of $100,000 gifts in Quebec is adding another chapter to Hyundai Canada’s fast-growing campaign against childhood cancer. Hyundai Hope on Wheels announced $200,000 for the Montreal Children’s Hospital Foundation and Fondation CHUS in Sherbrooke, with the money directed toward pediatric cancer research, specialized care and support for families.
The Quebec grants form part of Hyundai Hope on Wheels’ commitment of more than $4.1 million across Canada in 2026. Behind the large national figure are two distinctly local goals: giving Montreal researchers a more detailed way to study tumours and helping children in the Eastern Townships receive sophisticated oncology care without routinely travelling to Montreal.
Quebec’s $200,000 Is Being Split Between Two Different Priorities
Hyundai Hope on Wheels is dividing its latest Quebec contribution evenly. The Montreal Children’s Hospital Foundation will receive $100,000, while Fondation CHUS in Sherbrooke will receive another $100,000. The grants were presented during Handprint Ceremonies held in the two cities during the first week of October. Hyundai says the Quebec funding forms part of a 2026 Canadian commitment exceeding $4.1 million for pediatric cancer research, clinical care and programs supporting children and their families.
Although the cheques are identical in size, their purposes are quite different. Montreal intends to put the money toward advanced research technology capable of examining tumours at extremely high resolution. Sherbrooke, meanwhile, is directing its contribution toward its Pediatric Oncology Fund, which helps maintain specialized local treatment and access to research protocols. That distinction illustrates how pediatric cancer funding can operate on two fronts at once: investing in discoveries that may influence future treatments while also strengthening the day-to-day care available to children currently undergoing therapy.
Montreal Will Use Its Grant to Examine Tumours Cell by Cell
The Montreal Children’s Hospital Foundation plans to use its entire $100,000 contribution toward a 10x Genomics Spatial Biology Platform developed through a joint initiative involving McGill University and the McGill University Health Centre. The technology is designed to let researchers study individual cells while preserving information about where those cells were situated inside a tumour. Traditional approaches can reveal considerable molecular detail, but spatial techniques add an important layer by showing how different types of cells are organized and interact.
That matters because a cancerous tumour is more complicated than a collection of identical malignant cells. Researchers can examine relationships among tumour cells, immune cells and surrounding healthy tissue, creating a more detailed molecular map of the disease. Hyundai and the hospital foundation say the platform could help researchers investigate how childhood cancers develop, spread and respond to treatment. The longer-term ambition is to identify biological vulnerabilities that might eventually lead to more precise therapies, potentially attacking cancer more effectively while limiting damage to healthy tissue in growing children.
Sherbrooke’s Grant Is Designed to Keep More Care Close to Home
In Sherbrooke, the $100,000 contribution is supporting Fondation CHUS’s Pediatric Oncology Fund. The fund was established to strengthen specialized cancer treatment for children in the Eastern Townships and help the local medical team participate in research protocols through the Children’s Oncology Group, an international pediatric cancer research network. Fondation CHUS says its pediatric oncology program has made substantial progress toward allowing families to obtain complex treatment without repeatedly travelling to a larger centre.
The foundation reports that roughly 95% of children from the Estrie region who require cancer treatment can now receive that treatment in Sherbrooke. Only a few years ago, many had to go to Montreal. For a family already balancing chemotherapy schedules, school, work and the emotional weight of a cancer diagnosis, geography can become another burden. Fondation CHUS reported that its Pediatric Oncology Fund had reached $5 million by September 2026, halfway toward a stated $10-million goal. Hyundai’s contribution therefore joins a broader effort to make specialized regional pediatric oncology sustainable over the long term.
Rosalie’s Experience Shows What Months of Treatment Can Mean
The Montreal Handprint Ceremony centred partly on Rosalie, a five-year-old patient ambassador whose experience gave the funding announcement a human scale. According to Hyundai Canada, Rosalie was three when she was diagnosed with Ewing sarcoma, a rare cancer affecting bone or soft tissue. Her treatment included chemotherapy approximately every two weeks for nine months. That meant a period of childhood dominated not by an ordinary daycare schedule but by hospital visits, treatment cycles and the uncertainty experienced by families dealing with serious illness.
Her care involved more than medication. Hyundai highlighted the role of Child Life Services and music therapy in helping Rosalie maintain moments of normal childhood during treatment. Her mother, Marie-Claude Proulx, works at the Montreal Children’s Hospital, creating the unusual experience of being both a healthcare professional and the parent of a child with cancer. Rosalie’s story underscores why cancer programs increasingly consider quality of life alongside survival. Successful pediatric oncology involves treating a tumour, but it also involves helping a child continue to play, learn, connect with family and cope with months of disruptive care.
William’s Recovery Became a Story of Returning to the Ice
Sherbrooke’s ceremony featured a very different cancer journey. William Picard was approaching his 18th birthday when a lump on his neck led to testing and a diagnosis of early-stage Hodgkin lymphoma on Boxing Day 2022. Hyundai’s account says he had been feeling healthy enough to compete in high-level hockey before the diagnosis, illustrating how serious illness can interrupt an otherwise ordinary routine with little warning. Treatment forced him to step away from the remainder of his hockey season and begin chemotherapy.
William eventually worked toward returning to play with the College Champlain-Lennoxville Cougars. His recovery also turned into a fundraising effort: after treatment, he organized a volleyball tournament that raised $10,000 for the hospital foundation. Stories like his help explain why community cancer programs extend beyond the treatment room. Friends, teammates, healthcare workers and family members often become part of a patient’s support system. They also demonstrate why keeping care geographically closer to home can matter. Remaining connected to school, sport and familiar communities can reduce some of the disruption surrounding months of medical treatment.
Childhood Cancer Is Rare but Still Affects About 1,000 Canadian Children Each Year
Childhood cancer represents a relatively small share of all Canadian cancer diagnoses, but its effect is disproportionate because patients face serious illness so early in life. The Public Health Agency of Canada estimates that approximately 1,000 children under age 15 are diagnosed with cancer nationally each year. More than 86% survive for at least five years after diagnosis, reflecting decades of progress in treatment, supportive care and clinical research.
Survival, however, is only one measure of the burden. Canadian public-health researchers reported in 2025 that more than one in 1,000 Canadians younger than 20 had been diagnosed with cancer before age 15. Survivors can require long-term follow-up because chemotherapy, radiation and other intensive treatments may produce health effects years after the original disease has been controlled. That helps explain Hyundai Hope on Wheels’ combination of research, treatment and family-support funding. With a growing population of childhood-cancer survivors, healthcare systems must address both the immediate goal of curing disease and the longer-term challenge of helping those survivors remain healthy throughout adulthood.
Clinical Research Is Becoming a Bigger Part of Hyundai’s Canadian Program
One of the biggest additions to Hyundai Hope on Wheels in 2026 is its partnership with the C17 Council, which represents Canada’s pediatric hematology, oncology and stem-cell-transplant programs. The organizations established a research competition offering four grants of $250,000 each over two years. That creates a $1-million research pool for Canadian-led projects intended to improve treatment outcomes, therapeutic options or quality of life for young cancer patients. A separate infrastructure initiative also offers support for strengthening pediatric oncology clinical-trial capacity.
The need for trial infrastructure is measurable. Public Health Agency of Canada data show considerable differences in clinical-trial participation depending on childhood cancer type. Historical national data indicate that about 48% of children with leukemia were enrolled in a therapeutic clinical trial for initial treatment, compared with 14% of children with non-central-nervous-system solid tumours, 13% with lymphoma and 7% with central-nervous-system tumours. Trial availability is one important constraint. National networks such as C17 are intended to make collaborative research possible across relatively small pediatric patient populations.
Hyundai’s Canadian Cancer Program Has Expanded Quickly
Hyundai Hope on Wheels is still relatively new in Canada. Hyundai Auto Canada and its dealership network formally launched the Canadian organization in February 2025, announcing plans to distribute more than $4 million during its inaugural year. Early grants included $1 million each for SickKids in Toronto and CHU Sainte-Justine in Montreal, alongside additional donations to pediatric oncology centres around the country.
The 2026 commitment has grown to more than $4.1 million. Taken together, the announced annual commitments for the program’s first two years exceed $8.1 million, although those figures represent commitments across separate campaign years rather than one single 2026 donation pool. The approach also broadened in its second year through the C17 partnership and a stronger focus on national research infrastructure. Hyundai’s model is notable because it mixes large research grants with smaller hospital-level contributions. A $1-million national research program can support projects with broad scientific ambitions, while a $100,000 local grant can purchase equipment, sustain a regional program or address an immediate need identified by a hospital foundation.
Vehicle Sales Help Create the Funding Pool
Hyundai Hope on Wheels is structured so that ordinary vehicle sales contribute to its charitable funding. Hyundai says a portion of every new Hyundai sold in Canada goes toward the program, with support from its nationwide dealer network. When the Canadian organization launched in 2025, Hyundai said participating dealers would begin contributing through new-vehicle sales made from January 1 of that year. The 2026 program is supported by Hyundai Auto Canada and more than 225 dealerships across the country.
That mechanism connects the company’s commercial activity with a recurring source of charitable funding rather than relying entirely on occasional corporate cheques. It also makes the size of Hyundai’s dealer network significant to the program’s national scope. The company currently identifies 16 Canadian pediatric oncology centres as being affected by the initiative and promotes a combination of research grants and impact donations. For hospitals, predictable multi-year philanthropic programs can be especially valuable when government funding does not cover every piece of research equipment, patient-support service or experimental research project that clinicians and foundations would like to pursue.
The Handprint Ceremonies Are Meant to Keep Children at the Centre
The most recognizable feature of Hyundai Hope on Wheels is not a cheque presentation. At each Handprint Ceremony, children affected by cancer place painted handprints on a white Hyundai vehicle. The vehicle then travels as a visible collection of those individual marks. Hyundai has used the tradition for years through the Hope on Wheels program, which began in the United States in 1998 before the Canadian initiative was established in 2025.
The symbolism matters because large national funding totals can otherwise become abstract. A $4.1-million commitment can be measured in grants, equipment and research programs, but the handprints represent individual patients whose childhoods have been interrupted by treatment. They also give children a visible role in events that could easily become corporate ceremonies dominated by executives and oversized cheques. In Quebec, the stories of Rosalie and William turned the funding into something more concrete: one child endured nine months of chemotherapy, while one teenager temporarily traded competitive hockey for cancer treatment before finding his way back to sport and fundraising.
Hyundai’s Quebec Campaign Is Not Finished Yet
The Montreal and Sherbrooke donations are not scheduled to be the final Quebec stops of Hyundai Hope on Wheels’ 2026 campaign. Hyundai said on October 9 that the national tour had four stops remaining. After additional activity in Ontario, the organization plans to return to Quebec for a Handprint Ceremony in Quebec City on October 22 and another in Montreal on October 23. Those future events are expected to continue distributing funding as the second Canadian tour reaches its final stage.
The larger significance of the Quebec announcement will ultimately depend on what the grants enable after the ceremonies end. In Montreal, that means putting new spatial-biology research capability into scientists’ hands. In Sherbrooke, it means maintaining access to specialized treatment and research protocols closer to the communities families call home. Across Canada, Hyundai’s more-than-$4.1-million commitment is increasingly divided among research, clinical-trial infrastructure, care and family support. The dollar figure attracts attention, but the longer-term measure will be whether those investments translate into better treatments, easier access to care and healthier lives after childhood cancer.
